167 related articles for article (PubMed ID: 14759812)
1. Enhanced gene delivery by avidin-displaying baculovirus.
Räty JK; Airenne KJ; Marttila AT; Marjomäki V; Hytönen VP; Lehtolainen P; Laitinen OH; Mähönen AJ; Kulomaa MS; Ylä-Herttuala S
Mol Ther; 2004 Feb; 9(2):282-91. PubMed ID: 14759812
[TBL] [Abstract][Full Text] [Related]
2. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery.
Kaikkonen MU; Lesch HP; Pikkarainen J; Räty JK; Vuorio T; Huhtala T; Taavitsainen M; Laitinen T; Tuunanen P; Gröhn O; Närvänen A; Airenne KJ; Ylä-Herttuala S
Gene Ther; 2009 Jul; 16(7):894-904. PubMed ID: 19440224
[TBL] [Abstract][Full Text] [Related]
3. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.
Lehtolainen P; Wirth T; Taskinen AK; Lehenkari P; Leppänen O; Lappalainen M; Pulkkanen K; Marttila A; Marjomäki V; Airenne KJ; Horton M; Kulomaa MS; Ylä-Herttuala S
Gene Ther; 2003 Dec; 10(25):2090-7. PubMed ID: 14595382
[TBL] [Abstract][Full Text] [Related]
4. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
Campos SK; Parrott MB; Barry MA
Mol Ther; 2004 Jun; 9(6):942-54. PubMed ID: 15194061
[TBL] [Abstract][Full Text] [Related]
5. Targeting and purification of metabolically biotinylated baculovirus.
Kaikkonen MU; Viholainen JI; Närvänen A; Ylä-Herttuala S; Airenne KJ
Hum Gene Ther; 2008 Jun; 19(6):589-600. PubMed ID: 18479188
[TBL] [Abstract][Full Text] [Related]
6. Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.
Lesch HP; Pikkarainen JT; Kaikkonen MU; Taavitsainen M; Samaranayake H; Lehtolainen-Dalkilic P; Vuorio T; Määttä AM; Wirth T; Airenne KJ; Ylä-Herttuala S
Hum Gene Ther; 2009 Aug; 20(8):871-82. PubMed ID: 19419273
[TBL] [Abstract][Full Text] [Related]
7. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.
Morizono K; Xie Y; Helguera G; Daniels TR; Lane TF; Penichet ML; Chen IS
J Gene Med; 2009 Aug; 11(8):655-63. PubMed ID: 19455593
[TBL] [Abstract][Full Text] [Related]
8. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.
Purow B; Staveley-O'Carroll K
J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950
[TBL] [Abstract][Full Text] [Related]
9. Development of adenovirus immobilization strategies for in situ gene therapy.
Hu WW; Lang MW; Krebsbach PH
J Gene Med; 2008 Oct; 10(10):1102-12. PubMed ID: 18618417
[TBL] [Abstract][Full Text] [Related]
10. Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy.
Qu W; Chen WH; Kuang Y; Zeng X; Cheng SX; Zhou X; Zhuo RX; Zhang XZ
Mol Pharm; 2013 Jan; 10(1):261-9. PubMed ID: 23146022
[TBL] [Abstract][Full Text] [Related]
11. Introduction of histidine residues into avidin subunit interfaces allows pH-dependent regulation of quaternary structure and biotin binding.
Nordlund HR; Hytönen VP; Laitinen OH; Uotila ST; Niskanen EA; Savolainen J; Porkka E; Kulomaa MS
FEBS Lett; 2003 Dec; 555(3):449-54. PubMed ID: 14675754
[TBL] [Abstract][Full Text] [Related]
12. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.
Campos SK; Barry MA
Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233
[TBL] [Abstract][Full Text] [Related]
13. Switchavidin: reversible biotin-avidin-biotin bridges with high affinity and specificity.
Taskinen B; Zauner D; Lehtonen SI; Koskinen M; Thomson C; Kähkönen N; Kukkurainen S; Määttä JA; Ihalainen TO; Kulomaa MS; Gruber HJ; Hytönen VP
Bioconjug Chem; 2014 Dec; 25(12):2233-43. PubMed ID: 25405260
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules.
Lehtolainen P; Taskinen A; Laukkanen J; Airenne KJ; Heino S; Lappalainen M; Ojala K; Marjomäki V; Martin JF; Kulomaa MS; Ylä-Herttuala S
J Biol Chem; 2002 Mar; 277(10):8545-50. PubMed ID: 11741995
[TBL] [Abstract][Full Text] [Related]
15. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.
Maldiney T; Kaikkonen MU; Seguin J; le Masne de Chermont Q; Bessodes M; Airenne KJ; Ylä-Herttuala S; Scherman D; Richard C
Bioconjug Chem; 2012 Mar; 23(3):472-8. PubMed ID: 22250884
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.
Soininen SK; Lehtolainen-Dalkilic P; Karppinen T; Puustinen T; Dragneva G; Kaikkonen MU; Jauhiainen M; Allart B; Selwood DL; Wirth T; Lesch HP; Määttä AM; Mönkkönen J; Ylä-Herttuala S; Ruponen M
Eur J Pharm Sci; 2012 Dec; 47(5):848-56. PubMed ID: 22985874
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo.
Murugan S; Saarela U; Airenne K; Shan J; Skovorodkin I; Ylä-Herttuala S; Vainio SJ
Genesis; 2012 Sep; 50(9):693-9. PubMed ID: 22467513
[TBL] [Abstract][Full Text] [Related]
18. Avidin-biotin technology in targeted therapy.
Lesch HP; Kaikkonen MU; Pikkarainen JT; Ylä-Herttuala S
Expert Opin Drug Deliv; 2010 May; 7(5):551-64. PubMed ID: 20233034
[TBL] [Abstract][Full Text] [Related]
19. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells.
Ojala K; Mottershead DG; Suokko A; Oker-Blom C
Biochem Biophys Res Commun; 2001 Jun; 284(3):777-84. PubMed ID: 11396970
[TBL] [Abstract][Full Text] [Related]
20. Virus immobilization on biomaterial scaffolds through biotin-avidin interaction for improving bone regeneration.
Hu WW; Wang Z; Krebsbach PH
J Tissue Eng Regen Med; 2016 Feb; 10(2):E63-72. PubMed ID: 23798490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
